Product Information
RUFINAMIDE 400 MG TABLET is a generic product labeled by Glenmark Pharmaceuticals Inc., USA, priced at $1.3913 per EA under NDC 68462071408. Its NADAC has been published 259 times since Oct 20, 2021.
FDA first approved this application on May 16, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
400 mg/1
Manufacturer
Glenmark Pharmaceuticals Inc., USANDC
68462071408
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RUFINAMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA205075FDA Approved
5/16/2016
TE Code
AB
On Market Since
5/16/2016
Price Statistics
The NADAC for RUFINAMIDE 400 MG TABLET has been published 259 times since Oct 20, 2021, and over the history we have for it it has declined 76.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.3913 per EA |
|---|---|
| All-time high | $5.9562 (Jan 12, 2022) |
| All-time low | $1.3608 (May 20, 2026) |
| 52-week high | $1.7050 |
| 52-week low | $1.3608 |
| Median price | $3.5684 |
| Average price | $3.3261 |
| Largest weekly change | -38.3% (May 22, 2024) |
| Weeks tracked | 259 |
| Tracking since | Oct 20, 2021 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Glenmark Pharmaceuticals Inc., USA manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
rufinamide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RUFINAMIDE 400 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for RUFINAMIDE 400 MG TABLET, manufactured by Glenmark Pharmaceuticals Inc., USA, is $1.3913 per EA (NDC 68462071408), effective Sep 30, 2026.
How has the price of RUFINAMIDE 400 MG TABLET changed over time?
Over the history we have for it, the NADAC for RUFINAMIDE 400 MG TABLET has declined 76.6%. It has been tracked across 259 weekly CMS publications since Oct 20, 2021.
What are the highest and lowest recorded NADAC prices for RUFINAMIDE 400 MG TABLET?
Since Oct 20, 2021, the NADAC for RUFINAMIDE 400 MG TABLET has ranged from a low of $1.3608 (May 20, 2026) to a high of $5.9562 (Jan 12, 2022), with a median of $3.5684 per EA.
Are there cheaper alternatives to RUFINAMIDE 400 MG TABLET?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as RUFINAMIDE 400 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures RUFINAMIDE 400 MG TABLET?
RUFINAMIDE 400 MG TABLET (NDC 68462071408) is labeled by Glenmark Pharmaceuticals Inc., USA, and CMS classifies it as a generic product.